Opaleye Management Inc. Sutro Biopharma, Inc. Transaction History

Opaleye Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.07 - $4.54 $624,086 - $1.37 Million	301,491 New	301,491 $1.29 Million
Q2 2023 Aug 14, 2023	BUY	$4.25 - $5.88 $1.3 Million - $1.81 Million	307,000 New	307,000 $1.43 Million
Q2 2022 Aug 15, 2022	SELL	$3.41 - $8.95 $306,831 - $805,320	-89,980 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$7.78 - $15.31 $4.59 Million - $9.03 Million	-590,020 Reduced 86.77%	89,980 $740,000
Q4 2021 Feb 14, 2022	BUY	$14.25 - $23.53 $2.03 Million - $3.35 Million	142,200 Added 26.44%	680,000 $10.1 Million
Q3 2021 Nov 16, 2021	BUY	$16.88 - $22.38 $690,392 - $915,342	40,900 Added 8.23%	537,800 $10.2 Million
Q2 2021 Aug 16, 2021	BUY	$18.03 - $23.82 $2.79 Million - $3.69 Million	154,950 Added 45.31%	496,900 $9.24 Million
Q1 2021 May 18, 2021	BUY	$20.29 - $27.54 $400,727 - $543,915	19,750 Added 6.13%	341,950 $7.78 Million
Q4 2020 Feb 12, 2021	BUY	$10.16 - $23.98 $1.79 Million - $4.23 Million	176,200 Added 120.68%	322,200 $7 Million
Q3 2020 Nov 16, 2020	BUY	$7.44 - $13.15 $1.09 Million - $1.92 Million	146,000 New	146,000 $1.47 Million

140

62.4M

77.1K

31.4K

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $98.1M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.